{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Solid+Malignant+Tumors&page=15", "query": { "condition": "Other Solid Malignant Tumors", "page": 15 }, "page_size": 10 }, "pagination": { "page": 15, "page_size": 10, "total_count": 342, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Solid+Malignant+Tumors&page=16&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Other+Solid+Malignant+Tumors&page=14&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:07:23.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04973163", "title": "A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors, KRAS Mutation" ], "interventions": [ { "name": "BI 1823911", "type": "DRUG" }, { "name": "BI 1701963", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-09-09", "completion_date": "2026-12-27", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 3, "location_summary": "New York, New York • Dallas, Texas • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04973163" }, { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Small Cell and Non-small Cell Lung Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Other Specified Sites of Skin", "Malignant Melanoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT03157128", "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "Medullary Thyroid Cancer", "Colon Cancer", "Any Solid Tumor" ], "interventions": [ { "name": "LOXO-292", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 857, "start_date": "2017-05-02", "completion_date": "2027-02", "has_results": true, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 41, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03157128" }, { "nct_id": "NCT07213609", "title": "A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neoplasms, Colorectal", "Neoplasms" ], "interventions": [ { "name": "GSK5460025", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2025-10-20", "completion_date": "2028-10-27", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 4, "location_summary": "Aurora, Colorado • Detroit, Michigan • Canton, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Canton", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT07213609" }, { "nct_id": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Solid Tumor", "Refractory Solid Tumor" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Dinutuximab", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2020-11-09", "completion_date": "2025-08-19", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04238819" }, { "nct_id": "NCT05544552", "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Urothelial Carcinoma", "Metastatic Urothelial Carcinoma", "Solid Tumor", "Urothelial Carcinoma", "Solid Tumor, Adult", "Bladder Cancer", "Non-muscle-invasive Bladder Cancer", "FGFR3 Gene Mutation", "FGFR3 Gene Alteration", "Advanced Solid Tumor", "Advanced Urothelial Carcinoma", "Urinary Tract Cancer", "Urinary Tract Tumor", "Urinary Tract Carcinoma" ], "interventions": [ { "name": "TYRA-300", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tyra Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 310, "start_date": "2022-11-22", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 7, "location_summary": "Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Worchester", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05544552" }, { "nct_id": "NCT00479128", "title": "Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Urethral Cancer" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 80, "start_date": "2006-09-28", "completion_date": "2026-04-14", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00479128" }, { "nct_id": "NCT02784795", "title": "A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor", "Breast Cancer", "Colon Cancer", "Cholangiocarcinoma", "Soft Tissue Sarcoma" ], "interventions": [ { "name": "LY3039478", "type": "DRUG" }, { "name": "Taladegib", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "LY3023414", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2016-11-04", "completion_date": "2020-02-13", "has_results": true, "last_update_posted_date": "2025-08-21", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 4, "location_summary": "Miami, Florida • Detroit, Michigan • New York, New York + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02784795" }, { "nct_id": "NCT06777316", "title": "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma (Icc)", "Cholangiocarcinoma", "Other Solid Tumors, Adult", "FGFR2 Gene Fusion/Rearrangement", "FGFR2 Gene Amplification", "FGFR2 Gene Short Variants", "FGFR3 Gene Fusion/Rearrangement", "FGFR3 Gene Amplification", "FGFR3 Gene Short Variants", "FGFR2 Genetic Alterations", "FGFR3 Genetic Alterations", "Advanced Solid Tumors" ], "interventions": [ { "name": "CGT4859", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2025-01-22", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 12, "location_summary": "Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06777316" }, { "nct_id": "NCT04387071", "title": "CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Malignant Solid Neoplasm", "Metastatic Pancreatic Adenocarcinoma", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Malignant Solid Neoplasm" ], "interventions": [ { "name": "Agonistic Anti-OX40 Monoclonal Antibody INCAGN01949", "type": "BIOLOGICAL" }, { "name": "VLP-encapsulated TLR9 Agonist CMP-001", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2021-04-29", "completion_date": "2022-12-28", "has_results": true, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-15T04:07:23.956Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Newport Beach, California + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04387071" } ] }